Evaluating the Efficacy of Cresvin beta on Type 2 Diabetes Mellitus Management: A Randomized Comparative Clinical Trial

Background: In this current state, Type 2 Diabetes Mellitus (T2DM) is more prevalent in the population, and metformin is used as a first-line medication for treating it, but gradually prevalence and incident rate of T2DM is increased. There was an upsurge in the utilization of alternative therapies in managing of diabetes. Especially in diabetes, Herbal medicines are considered safe and reliable by the majority of the population. This research aims to estimate the safety and efficacy of poly herbal metabolite compounds of Cresvin beta capsules in adults with T2DM. Methods: In this study, 60 T2DM patients aged 18-60 years were randomly assigned to Groups A (30), receiving Metformin 500 mg twice a day after food, and Group B (30), receiving Cresvin beta capsule 500 mg twice a day, after food in a prospective, randomized and open-label clinical study. The in-silico simulation study was performed on selected plants major compounds on target protein Insulin-like Growth Factor-1 (1K3A). Results: The Cresvin beta is found to be safe and effective in the management of T2DM. The FBS, PPBS and HbA1c were significantly lowered (p<0.001) in posttreatment in both the Metformin and Cresvin beta capsules. Similarly, the levels of IGF1, adiponectin, EL-1, IL-6, and TNF-α showed significant alteration (p<0.001) after the treatment. The alterations found in the post-treatment results of Cresvin beta, including the reduced levels of creatinine and triglycerides, express the efficacy. Conclusion: The research results conclude, that the Cresvin beta capsule would be one of the suitable choices for increasing the efficacy in the management of diabetes mellitus.